BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 35288463)

  • 41. Functional HPV-specific PD-1
    Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
    Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intratumoral CD103
    Ren S; Lan T; Wu F; Chen S; Jiang X; Huo C; Li Z; Xie S; Wu D; Wang R; Li Y; Qiu L; Huang G; Li S; Wang X; Cen M; Cai T; Lin Z; Li J; Li B
    Cancer Commun (Lond); 2023 Oct; 43(10):1143-1163. PubMed ID: 37658605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of TCF-1 and its relationship between CD8+ TIL densities and immune checkpoints and their joint influences on prognoses of lung adenocarcinoma patients.
    Jiang K; Liu S; Chen Y; Xu Z; Xu Z; Qian B; Ding Q; Cui H; Sui Y; Cao D; Xu W; Shen M
    Thorac Cancer; 2023 Sep; 14(27):2745-2753. PubMed ID: 37536668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD4
    Piersiala K; Farrajota Neves da Silva P; Hjalmarsson E; Kolev A; Kågedal Å; Starkhammar M; Elliot A; Marklund L; Margolin G; Munck-Wikland E; Kumlien Georén S; Cardell LO
    Cancer Sci; 2021 Mar; 112(3):1048-1059. PubMed ID: 33462898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.
    Khan SM; Desai R; Coxon A; Livingstone A; Dunn GP; Petti A; Johanns TM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomarkers of tumor-reactive CD4
    Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
    Ji P; Chen D; Bian J; Xia R; Song X; Wen W; Zhang X; Zhu Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
    Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 53. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.
    Danahy DB; Kurup SP; Winborn CS; Jensen IJ; Harty JT; Griffith TS; Badovinac VP
    J Immunol; 2019 Aug; 203(3):725-735. PubMed ID: 31189573
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expansion of Tumor-Infiltrating CD8
    Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
    Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
    Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
    Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer.
    Guan Y; Kraus SG; Quaney MJ; Daniels MA; Mitchem JB; Teixeiro E
    Front Oncol; 2020; 10():586. PubMed ID: 32391270
    [No Abstract]   [Full Text] [Related]  

  • 59. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.
    Thibaudin M; Limagne E; Hampe L; Ballot E; Truntzer C; Ghiringhelli F
    Cancer Immunol Immunother; 2022 Oct; 71(10):2549-2563. PubMed ID: 35292828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.